ACH-2684: Additional Phase Ib data

Data from 30 patients with HCV genotype 1 infection in the Phase Ib portion of a 3-part, double-blind, U.S. Phase Ia/Ib trial showed that once-daily 100 mg oral ACH-2684 led to a mean maximum reduction in HCV RNA levels from baseline to day 3 of 3.36 log10 IU/mL vs. 0.68 log10 IU/mL for placebo. Additionally, once-daily 400 mg ACH-2684 led to a mean maximum reduction in HCV RNA from baseline to day 3 of 3.73 log10 IU/mL, while twice-daily 400 mg led to a mean maximum reduction of 4.16 log10 IU/mL. ACH-2684 was well tolerated with no viral breakthroughs observed during treatment. Additionally, no serious adverse events were reported and there were no patient discontinuations during treatment. ...